Comment on published article in Lupus : Autoimmune myelofibrosis with pancytopenia as a presenting manifestation of systemic lupus erythematosus responsive to mycophenolate mofetil;IVIG in myelofibrosis in SLE
Restricted accessEditorialFirst published online February, 2017
Comment on published article in Lupus : Autoimmune myelofibrosis with pancytopenia as a presenting manifestation of systemic lupus erythematosus responsive to mycophenolate mofetil;IVIG in myelofibrosis in SLE
UngprasertPChowdharyVRDavisMDMakolA. Autoimmune myelofibrosis with pancytopenia as a presenting manifestation of systemic lupus erythematosus responsive to mycophenolate mofetil. Lupus2016; 25: 427–430.
2.
Aharon A, Levy Y, Bar Dayan Y, et al. Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 1997; 6: 408–411.
3.
TajaJNihtyanovaSLMurrayCDDentonCPOngVH. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology (Oxford)2016; 55: 115–119.
4.
Abelha-AlexioJBernardoACostaL. Benefit of intravenous immunoglobulin in a patient with longstanding polymyositis/systemic sclerosis overlap syndrome. Acta Rheumatol Prot2015; 40: 176–178.
5.
CantariniLRiganteDVitaleA. Intravenous immunoglobulin (IVIG) in systemic sclerosis: A challenging yet promising future. Immunol Res2015; 61: 326–337.
6.
PoelmanCLHummersLKWigleyFMAndersonCBoinFShahAA. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J Rheumatol2015; 42: 236–242.
7.
MauhinWRivièreSCabaneJTievKP. Improvement in lung fibrosis using intravenous immunoglobulin in systemic sclerosis with myositis. Scand J Rheumatol2014; 43: 170–171.
8.
TakeharaKIhnHSatoS. A randomized double-blind, placebo-controlled trial: Intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol2013; 31: 151–156.
9.
KudoHJinninMYamaneK. Intravenous immunoglobulin treatment recovers the down-regulated levels of Th1 cytokines in the sera and skin of scleroderma patients. J Dermatol Sci2013; 69: 77–80.
10.
BalevaMNikolovK. The role of intravenous immunoglobulin preparations in the treatment of systemic sclerosis. Int Rheumatol2011; 2011: 892751–892751.
11.
IhnHMimuraYYazawaN. High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol2007; 156: 1058–1060.
12.
NacciFRighiAConfortiML. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: A pilot study. Ann Rheum Dis2007; 66: 977–979.
13.
Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 2002; 46: 1689–1690.
14.
AsanoYIhnHAsashimaN. A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology (Oxford)2005; 44: 824–826.
15.
LevyYAmitalHLangevitzP. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: An open-label study. Arthritis Rheum2004; 50: 1005–1007.
16.
AmitalHRewaldELevyY. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis2003; 62: 175–177.
